Patents by Inventor Jay Mei

Jay Mei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12208365
    Abstract: A gene chip includes a chip carrier, a plurality of DNA nanoballs assembled on the chip carrier, and a polymer film formed on the chip carrier and wrapping the DNA nanoballs. The polymer film includes at least one of a film of a positively charged polymer, a film of a positively charged polymer which is modified, a film of a zwitterionic polymer, and a composite polymer film. The composite polymer film is formed by a layer-by-layer self-assembly process of a positively charged polymer and a negatively charged polymer. The gene chip has good sequencing quality and different functions can be achieved by coating with different polymers, such as the chip surface rapidly drying out and surface non-specific adsorption. A method of preparing a gene chip is further disclosed.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: January 28, 2025
    Assignee: BGI SHENZHEN
    Inventors: Zhao-Hui Wang, Hui Wang, Cheng-Mei Xing, Han-Dong Li, Wen-Wei Zhang, Jay Willis Shafto, Mei-Hua Gong, Jin Yang, Yin-Ling Luo, Zhen-Hua Zhang, Yuan Li, Xue-Qin Jiang
  • Publication number: 20240400689
    Abstract: Provided are anti-CD276 antibodies, and anti-CD276/PD-L1 bispecific antibody molecules, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.
    Type: Application
    Filed: May 11, 2022
    Publication date: December 5, 2024
    Inventors: Hui YUWEN, Bing HOU, Tenteng LI, Peng CHEN, Min DENG, Bo SHAN, Jay MEI
  • Publication number: 20240262835
    Abstract: The present application provides novel PRMT5 and/or MTA-cooperative PRMT5 inhibiting compounds, or pharmaceutically acceptable salts thereof. The present application also provides pharmaceutical compositions comprising one or more of the compounds, or pharmaceutically acceptable salts thereof as an active ingredient, and the use of the compounds, or pharmaceutically acceptable salts thereof in the treatment of diseases or disorders, including cancers.
    Type: Application
    Filed: February 28, 2024
    Publication date: August 8, 2024
    Inventors: Ming ZHANG, Ya KONG, Lulu JIANG, Bin JIANG, Guoqiang DAI, Yulong HE, Bing HOU, Bo SHAN, Jay MEI
  • Publication number: 20240052052
    Abstract: The present disclosure provides anti-CD24 antibody, and anti-CD24/CD47 bispecific antibody molecules, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof
    Type: Application
    Filed: February 8, 2022
    Publication date: February 15, 2024
    Inventors: Peng CHEN, Bing HOU, Min DENG, Yun LIU, Jiamei LUO, Hui YUWEN, Bo SHAN, Jay MEI
  • Publication number: 20230339927
    Abstract: The present disclosure relates to novel compounds useful as inhibitors of ATR kinase, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 26, 2023
    Inventors: Bo SHAN, Bing HOU, Hui YUWEN, Zhongyang SHI, Peng CHEN, Jay MEI
  • Publication number: 20230295166
    Abstract: The present disclosure relates to novel compounds useful as inhibitors of ATR kinase, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.
    Type: Application
    Filed: August 6, 2021
    Publication date: September 21, 2023
    Inventors: Bo SHAN, Bing HOU, Hui YUWEN, Peng CHEN, Zhongyang SHI, Zhengsong GU, Ping CHEN, Zhenwei CAI, Jay MEI
  • Publication number: 20230212170
    Abstract: Provided are novel compounds useful as inhibitors of the KRAS protein, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.
    Type: Application
    Filed: June 3, 2021
    Publication date: July 6, 2023
    Inventors: Bo SHAN, Jian WANG, Bing HOU, Zhongyang SHI, Peng CHEN, Hui YUWEN, Xingquan MA, Zhu DU, Jay MEI
  • Publication number: 20230095569
    Abstract: Provided are anti-CLDN18 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: March 30, 2023
    Inventors: Bin HOU, Peng CHEN, Hui YUWEN, Bo SHAN, Jay MEI
  • Publication number: 20170216432
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Application
    Filed: November 11, 2016
    Publication date: August 3, 2017
    Inventors: Tom Daniel, Kenichi Takeshita, Kenneth Foon, Jay Mei
  • Patent number: 9492471
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: November 15, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Tom Daniel, Kenichi Takeshita, Kenneth Foon, Jay Mei
  • Publication number: 20150139979
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Application
    Filed: November 19, 2013
    Publication date: May 21, 2015
    Applicant: Celgene Avilomics Research, Inc.
    Inventors: Tom Daniel, Kenichi Takeshita, Kenneth Foon, Jay Mei
  • Publication number: 20150064173
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 5, 2015
    Applicant: Celgene Avilomics Research, Inc.
    Inventors: Tom Daniel, Kenichi Takeshita, Kenneth Foon, Jay Mei
  • Publication number: 20150064172
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 5, 2015
    Applicant: Celgene Avilomics Research, Inc.
    Inventors: Tom Daniel, Kenichi Takeshita, Kenneth Foon, Jay Mei
  • Publication number: 20140142129
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Application
    Filed: November 19, 2013
    Publication date: May 22, 2014
    Applicant: Celgene Avilomics Research, Inc,
    Inventors: Tom Daniel, Kenichi Takeshita, Kenneth Foon, Jay Mei
  • Publication number: 20140140991
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Application
    Filed: November 19, 2013
    Publication date: May 22, 2014
    Applicant: Celgene Avilomics Research, Inc.
    Inventors: Tom Daniel, Kenichi Takeshita, Kenneth Foon, Jay Mei
  • Publication number: 20140142128
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Application
    Filed: November 19, 2013
    Publication date: May 22, 2014
    Applicant: Celgene Avilomics Research, Inc.
    Inventors: Tom Daniel, Kenichi Takeshita, Kenneth Foon, Jay Mei
  • Publication number: 20070142305
    Abstract: The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell. proliferative disorders.
    Type: Application
    Filed: January 25, 2007
    Publication date: June 21, 2007
    Inventors: Chih Ho, Bengt Brunmark, Stuart Emanuel, Robert Galemmo, Dana Johnson, Donald Ludovici, Umar Maharoof, Jay Mei, Jan Sechler, Eric Strobel, Robert Tuman, Hwa Yen
  • Publication number: 20050130910
    Abstract: The present invention relates to immobilized N-substituted tricyclic 3-aminopyrazole compounds of Formula 1 as tools for the identification of bimolecular targets in cells of therapeutic significance, profiling the selectivity of compounds, prediction of possible related toxicities and exploration of mechanisms of action in biological systems for therapeutic indications related to compounds. These agents can be used to identify biomolecules with the potential to interact with the immobilized reagent. The identified biomolecule may be then be used as a therapeutic target, serve as a marker of drug action, or alternatively describe an untoward or toxic potential of the immobilized agent.
    Type: Application
    Filed: November 10, 2004
    Publication date: June 16, 2005
    Inventors: Chih Ho, Robert Galemmo, Dana Johnson, Jay Mei, Stanley Belkowski, Richard Connors